Learn More About CanSaRCC: A free registry to track tissues, blood samples and clinical data of Adults, Young Adults, Adolescents and Children with sarcoma across Canada

Latest News

Vision for Sarcoma Research & Clinical Trials - Hope for Sarcoma Patients

CanSaRCC Sarcoma Community Meet - Up, Feb 2026
Inaugural Virtual Meet-Up for Sarcoma Survivors, Patients & Families
Navigating Sarcoma Survivorship (Fear of Recurrence/Scanxiety/Rehab). moderated by Dr. Gupta. Dr. Gupta is a medical oncologist who works at University Health Network and The Hospital for Sick Children.
Download PDF
New Clinical Trials, 2026
*RECRUITING*
STRATEGIST-3: 2nd line GIST - imatinib vs IDRX-42, with crossover. Funding available for patient travel.
SARC-005: Angiogenic sarcomas (EHE, intimal, and H&N angiosarcoma) - oral immunotherapy. No funding available for patient travel. 
CHONQUER: 1st line conventional chondrosarcoma - placebo vs. ivosidenib. Funding available for patient travel.  
POLARIS: 2nd/3rd line leiomyosarcoma - gem/tax + ADIPEG20 vs. gem/tax + placebo. Weekly visits required. No funding available for patient travel.

*COMING SOON*
DCC3009: phase ½ study of pan-KIT inhibitor in patients with GIST. 
STRATEGIST-1: 1st line GIST - IDRX-42 vs. imatinib. 
EMBOLD: Osteosarcoma, liposarcoma, leiomyosarcoma, and other STS subtypes -      anti-B7H3 i.v. drug.

Cancer, Jan 2026
Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1
This study suggests that patients with NF1‐associated MPNSTs experience worse outcomes.
Download PDF
Cancer Medicine, Jan 2026
A Real-World Analysis of Outcomes in CIC-Rearranged Sarcomas
Complete resection is critical in CIC-rearranged sarcomas (CRS). Chemotherapy benefit remains uncertain, underscoring the need for improved local control and novel, biology-driven therapies.
Download PDF
European Journal of Cancer, Nov 2025
Incidence, prevalence and treatment of patients with Epithelioid Haemangioendothelioma (EHE) in Canada
This is the largest series of EHE patients describing sequential systemic therapies. The role of systemic therapy in EHE in improving survival remains unclear and prospective studies with comparative arms are needed to add further insight into this chronic disease
Download PDF
CanSaRCC Sarcoma Community Meet - Up, Oct 2025
Inaugural Virtual Meet-Up for Sarcoma Survivors, Patients & Families
Moderated by Dr. Jon Hunter. Dr. Hunter is a psychiatrist who works at Mount Sinai with a focus and expertise in psychosocial care of patients with sarcoma
Download PDF
No posters matched your search.
Contact Us today!

Contact Us

At cansarcc, we believe in fostering an environment where every voice is not only heard but also valued.  Whether your questions revolve around the specifics of cansarcc, insights on our ongoing projects, or exploring potential partnerships, we are here to help! Together we navigate the complexities of sarcoma diagnosis and management by bringing together diverse perspectives and interests. Thank you for being apart of this journey.



Email:
[email protected]

Mailing Address:
Canadian Sarcoma Reseach and Clinircal Collaboration (CanSaRCC)
Princess Margaret
OPG, 700 University Avenue
7th floor, Room #7-714
Toronto, ON M5G 1Z5
Canada